Pishtiwan H S Kalmet1, Sebastian Sanduleanu2, Sergey Primakov2, Guangyao Wu2, Arthur Jochems2, Turkey Refaee2, Abdalla Ibrahim2,3,4,5, Luca V Hulst1, Philippe Lambin2,3, Martijn Poeze1,6. 1. Maastricht University Medical Center+, Department of Trauma Surgery, Maastricht; 2. The D-Lab: Decision Support for Precision Medicine, GROW-School for Oncology and Developmental Biology, Maastricht University Medical Center+, Maastricht; 3. Department of Radiology and Nuclear Medicine, GROW - School for Oncology and Developmental Biology, Maastricht University Medical Centre+, Maastricht, The Netherlands; 4. Division of Nuclear Medicine and Oncological Imaging, Department of Medical Physics, Hospital Center Universitaire De Liege, Liege, Belgium; 5. Department of Nuclear Medicine and Comprehensive diagnostic center Aachen (CDCA), University Hospital RWTH Aachen University, Aachen, Germany. 6. Nutrim School for Nutrition, Toxicology and Metabolism, Maastricht University, Maastricht, The Netherlands.
Correction of conflict of interest statementOriginal statement: The authors declare that they have no conflict of interest.Corrected version:Conflict of interestThe authors, except dr. Philippe Lambin, declare that they have no conflict of interest.Dr. Lambin reports, within and outside the submitted work, grants/sponsored research agreements from Varian medical, Oncoradiomics, ptTheragnostic, Health Innovation Ventures and DualTpharma. He received an advisor/presenter fee and/or reimbursement of travel costs/external grant writing fee and/or in kind manpower contribution from Oncoradiomics, BHV, Merck and Convert pharmaceuticals. Dr Lambin has shares in the company Oncoradiomics SA and Convert pharmaceuticals SA and is co-inventor of two issued patents with royalties on radiomics (PCT/NL2014/050248, PCT/NL2014/050728) licensed to Oncoradiomics and one issue patent on mtDNA (PCT/EP2014/059089) licensed to ptTheragnostic/DNAmito, three non-patentable invention (softwares) licensed to ptTheragnostic/DNAmito, Oncoradiomics and Health Innovation Ventures.
Authors: Sergey P Primakov; Abdalla Ibrahim; Janita E van Timmeren; Guangyao Wu; Simon A Keek; Manon Beuque; Renée W Y Granzier; Elizaveta Lavrova; Madeleine Scrivener; Sebastian Sanduleanu; Esma Kayan; Iva Halilaj; Anouk Lenaers; Jianlin Wu; René Monshouwer; Xavier Geets; Hester A Gietema; Lizza E L Hendriks; Olivier Morin; Arthur Jochems; Henry C Woodruff; Philippe Lambin Journal: Nat Commun Date: 2022-06-14 Impact factor: 17.694